GRAIL Inc GRAL
News
Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail Trading Halted Ahead of FDA AdCom Meeting on Galleri Blood Test
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
GRAIL Reports Second Quarter 2026 Financial Results
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
GRAL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GRAIL, Inc. Securities Lawsuit - Contact The Gross Law Firm
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with SBS Law
GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL
GRAL Deadline: GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit
HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline
GRAL Investors Have Opportunity to Lead GRAIL, Inc. Securities Fraud Lawsuit with SBS Law
GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL
GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights


